pharma

Funds management

Regal Partners digests impact of Opthea failure

The failure of a clinical trial by biotech firm Opthea has caused shares in its backer Regal Partners to decline 52 per cent year-to-date and hit its funds under manageme...

Funds management

The healthcare stock opportunities presented from Ozempic’s success

Despite concerns that the popularity of pharmaceutical drug Ozempic is overblown, two fund managers are seeing stock picking opportunities from its success. ...

Funds management

Positive forecasts for healthcare stocks in long term

Global healthcare stocks are expected to perform strongly over the long term thanks to a huge boost in healthcare spending across developing and developed economies trigg...

Funds management

BofAML: Fund managers skewed to deflationary plays

Global fund managers are becoming more defensive in their asset allocation, according to Bank of America Merrill Lynch, as they adjust to the geopolitical environment. ...